GENE ONLINE|News &
Opinion
Blog

2020-03-24| COVID-19

Gilead’s Remdesivir Wins FDA’s Orphan Drug Designation for COVID-19 Treatment

by Ruchi Jhonsa
Share To

By Ruchi Jhonsa, Ph.D.

While the clinical trials of this promising drug against SARS-CoV-2 are still on, the FDA has provided a significant advantage to Gilead’s remdesivir today. In an announcement made this evening by the U.S. Food and Drug Administration, the agency has granted orphan drug designation to this promising experimental antiviral, a drug touted by the Trump government for COVID-19 treatment. This designation will grant Gilead Sciences, tax incentives as well as seven years of market exclusivity for drug production.

Remdesivir was already provided to patients with a severe infection on a compassionate use basis but ‘overwhelming demand’ in the past weeks forced the company to temporarily suspend drug access. This was after the news circulated about the recovery of the first coronavirus patient who happened to be under remdesivir treatment. Solid evidence from clinical trials in the coming months will tell us whether remdesivir could actually live up to its hype.

References
  1. https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/gileads-potential-coronavirus-treatment-gets-fdas-orphan-drug-label-idUSKBN21A3PR
  2. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=739020
  3. https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
LATEST
Eli Lilly Breaks Records with $9B Total Investment in Indiana Weight-loss Drug Expansion
2024-05-27
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
EVENT
Scroll to Top